Monthly Semaglutide Injection Shows Promise in Early Trials
Key Insights
A novel hydrogel formulation of semaglutide allows for a slow, steady release of the drug over one month, potentially reducing the frequency of injections.
Preclinical studies in rats demonstrated that the semaglutide-laden hydrogel achieved a consistent drug release profile over one month with no signs of inflammation.
Clinical trials in humans are anticipated within the next few years, pending successful testing in pigs, whose skin and endocrine systems are similar to humans.
A new hydrogel formulation of semaglutide, the active ingredient in popular drugs like Ozempic and Wegovy, could reduce the frequency of injections from weekly to monthly. Developed by French biotech company ADOCIA, the slow-release formulation aims to improve patient adherence and quality of life. The research was presented at the European Association for the Study of Diabetes (search) (EASD) annual meeting in Madrid.
The current weekly injection schedule of semaglutide poses a challenge for many patients. Studies show that only 39% to 67% of type 2 diabetics adhere to their weekly semaglutide injections for a year, and only 40% of patients using it for weight loss maintain the regimen for the same duration. A less frequent injection schedule could significantly improve these numbers.
How the Hydrogel Works
The new formulation, named AdoGel® Sema by ADOCIA, encases semaglutide in a hydrogel composed of two degradable polymers. Once injected under the skin, the hydrogel slowly dissolves, releasing a steady stream of semaglutide over the course of a month. This method aims to maintain stable drug levels in the body, potentially improving efficacy and reducing side effects.
"A small dollop of gel, known as a 'depot,' of the semaglutide-laden hydrogel is injected under the skin," explained Dr. Claire Mégret, director of clinical and preclinical development for ADOCIA. The hydrogel is designed to limit the initial burst release of semaglutide while ensuring controlled dissolving over one month.
Preclinical Results
In preclinical studies, the hydrogel demonstrated promising results. In vitro tests showed extended and constant release rates of semaglutide over one to three months, with the release duration being customizable through adjustments to the hydrogel's properties. When tested in rats, a single injection of the hydrogel-based therapy resulted in a regular release of semaglutide over a one-month period with no signs of inflammation.
Next Steps
The researchers plan to test the hydrogel platform in pigs, whose skin and endocrine systems are more similar to those of humans. "Next we will be testing the hydrogel platform in pigs... If that goes well, we will move forward the platform development by expecting clinical trials within the next few years," said Dr. Mégret.
If human trials prove successful, this monthly injection could offer a significant advantage over the current weekly regimen, potentially improving adherence and outcomes for individuals with type 2 diabetes (search) and those seeking weight management solutions. The semaglutide-laden hydrogel doesn’t require a special syringe, researchers said. An off-the-shelf needle can place the wad of gel under the skin.